Compare Novartis AG (NVS) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard International High Dividend Yield ETF — how do they compare? Novartis AG trades at $139.66 (market cap $262.64B), while Vanguard International High Dividend Yield ETF trades at $105.38. The key difference: Novartis AG pays a 3.44% dividend while Vanguard International High Dividend Yield ETF pays none, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VYMI | |
|---|---|---|
Market Cap | $262.64B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $107.13 |
52-Week Low | $121.80 | $82.92 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
VYMI trades at $106.20, down 0.78% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF has gained attention for its international high-dividend yield strategy, recently hitting a 52-week high near current levels. Recent news highlights its outperformance versus domestic dividend ETFs and growing institutional interest.
The outlook remains positive given Vanguard's bullish stance on international developed markets and the ETF's strong dividend growth. Key risks include currency fluctuations and global economic volatility. With technical support at $105-106 and resistance at $107-108, the ETF offers income-focused exposure to international equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
